Depomed Stock Price, News & Analysis (NASDAQ:DEPO)

$7.79 -0.36 (-4.42 %)
(As of 01/19/2018 12:30 PM ET)
Previous Close$8.15
Today's Range$7.53 - $8.25
52-Week Range$4.31 - $18.64
Volume1.41 million shs
Average Volume967,792 shs
Market Capitalization$490.87 million
P/E Ratio-4.26
Dividend YieldN/A
Beta1.29

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Generic Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:DEPO
CUSIP24990810
Phone+1-510-7448000

Debt

Debt-to-Equity Ratio2.90%
Current Ratio0.83%
Quick Ratio0.79%

Price-To-Earnings

Trailing P/E Ratio-4.2568306010929
Forward P/E Ratio-5.81
P/E GrowthN/A

Sales & Book Value

Annual Sales$455.90 million
Price / Sales1.08
Cash Flow$0.59 per share
Price / Cash13.10
Book Value$4.07 per share
Price / Book1.91

Profitability

Trailing EPS($1.83)
Net Income$-88,720,000.00
Net Margins-27.73%
Return on Equity-51.07%
Return on Assets-10.00%

Miscellaneous

Employees490
Outstanding Shares63,010,000

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed Inc (NASDAQ:DEPO) posted its quarterly earnings results on Tuesday, November, 7th. The specialty pharmaceutical company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. The specialty pharmaceutical company earned $95.40 million during the quarter, compared to analysts' expectations of $99.11 million. Depomed had a negative return on equity of 51.07% and a negative net margin of 27.73%. The company's quarterly revenue was down 13.7% compared to the same quarter last year. During the same period last year, the firm earned $0.28 EPS. View Depomed's Earnings History.

When will Depomed make its next earnings announcement?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, February, 19th 2018. View Earnings Estimates for Depomed.

Where is Depomed's stock going? Where will Depomed's stock price be in 2018?

8 brokers have issued 12 month price targets for Depomed's shares. Their predictions range from $5.00 to $24.00. On average, they anticipate Depomed's stock price to reach $11.75 in the next year. View Analyst Ratings for Depomed.

What are Wall Street analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
  • 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:

  • James P. Fogarty CPA, Chairman of the Board (Age 49)
  • Arthur J. Higgins, President, Chief Executive Officer, Director (Age 61)
  • August J. Moretti, Chief Financial Officer, Senior Vice President (Age 66)
  • Santosh J. Vetticaden M.D. Ph.D., Senior Vice President, Chief Medical and Scientific Officer
  • Matthew M. Gosling, Senior Vice President, General Counsel (Age 46)
  • Sharon D. Larkin, Senior Vice President - Human Resources and Administration. (Age 53)
  • Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality (Age 49)
  • Karen A. Dawes, Independent Director (Age 64)
  • Louis J. Lavigne Jr., Independent Director (Age 69)
  • William T. McKee CPA, Independent Director (Age 55)

Who owns Depomed stock?

Depomed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.67%), Acadian Asset Management LLC (0.56%), Fox Run Management L.L.C. (0.09%) and Nisa Investment Advisors LLC (0.06%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Who bought Depomed stock? Who is buying Depomed stock?

Depomed's stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Fox Run Management L.L.C., Schwab Charles Investment Management Inc. and Nisa Investment Advisors LLC. View Insider Buying and Selling for Depomed.

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of Depomed stock can currently be purchased for approximately $7.79.

How big of a company is Depomed?

Depomed has a market capitalization of $490.87 million and generates $455.90 million in revenue each year. The specialty pharmaceutical company earns $-88,720,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Depomed employs 490 workers across the globe.

How can I contact Depomed?

Depomed's mailing address is 7999 Gateway Blvd Ste 300, NEWARK, CA 94560-1188, United States. The specialty pharmaceutical company can be reached via phone at +1-510-7448000 or via email at [email protected]


MarketBeat Community Rating for Depomed (DEPO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  371 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  627
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Depomed (NASDAQ:DEPO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.382.382.222.50
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.75$11.75$12.67$17.00
Price Target Upside: 41.06% upside41.06% upside135.00% upside57.41% upside

Depomed (NASDAQ:DEPO) Consensus Price Target History

Price Target History for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2017Royal Bank of CanadaSet Price TargetHold$9.00MediumView Rating Details
12/7/2017Piper Jaffray CompaniesReiterated RatingHold$9.00HighView Rating Details
12/5/2017MizuhoUpgradeNeutral -> Buy$9.00HighView Rating Details
11/9/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
8/8/2017Janney Montgomery ScottDowngradeBuy -> Neutral$18.00 -> $8.00HighView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/AView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/AView Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Depomed (NASDAQ:DEPO) Earnings History and Estimates Chart

Earnings by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ DEPO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/19/2018$0.12N/AView Earnings Details
11/7/2017Q3 2017$0.12$0.14$99.11 million$95.40 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.09($0.43)$100.40 million$100.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
11/1/2010Q3 2010($0.02)$0.04ViewN/AView Earnings Details
8/5/2010Q2 2010$0.04$0.08ViewN/AView Earnings Details
4/29/2010Q1 2010($0.07)($0.07)ViewN/AView Earnings Details
3/4/2010Q4 2009($0.13)($0.07)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.06)($0.10)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.19)($0.19)ViewN/AView Earnings Details
5/4/2009Q1 2009($0.22)($0.20)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.26)($0.22)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.15)($0.12)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.22)($0.03)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.16)ViewN/AView Earnings Details
3/6/2008Q4 2007$0.40$0.44ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Depomed (NASDAQ:DEPO) Earnings Estimates

2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Depomed (NASDAQ:DEPO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Depomed (NASDAQ DEPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 90.76%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ DEPO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Arthur J. HigginsInsiderBuy75,000$8.16$612,000.00View SEC Filing  
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.0026,680View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.0073,086View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.8084,336View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00109,297View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00124,297View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.0022,879View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00137,737View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.0021,319View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.5011,396View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.009,084View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.4061,698View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Depomed (NASDAQ DEPO) News Headlines

Source:
DateHeadline
VTVT Steadying Up, ADVM Advances, AGRX Bouncing BackVTVT Steadying Up, ADVM Advances, AGRX Bouncing Back
www.nasdaq.com - January 17 at 9:17 AM
Depomed Inc (DEPO) Given Consensus Rating of "Hold" by BrokeragesDepomed Inc (DEPO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 15 at 7:42 PM
Zacks: Brokerages Expect Depomed Inc (DEPO) Will Post Quarterly Sales of $92.77 MillionZacks: Brokerages Expect Depomed Inc (DEPO) Will Post Quarterly Sales of $92.77 Million
www.americanbankingnews.com - January 12 at 4:42 AM
Zacks: Brokerages Expect Depomed Inc (DEPO) Will Announce Earnings of $0.10 Per ShareZacks: Brokerages Expect Depomed Inc (DEPO) Will Announce Earnings of $0.10 Per Share
www.americanbankingnews.com - January 10 at 7:38 PM
BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium PharmaceuticalBRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical
www.reuters.com - January 10 at 9:33 AM
Depomed Announces Closing of NUCYNTA Commercialization Agreement With Collegium PharmaceuticalDepomed Announces Closing of NUCYNTA Commercialization Agreement With Collegium Pharmaceutical
finance.yahoo.com - January 10 at 9:33 AM
An Intrinsic Value Calculation For Depomed Inc (NASDAQ:DEPO) Shows It’s 47.90% UndervaluedAn Intrinsic Value Calculation For Depomed Inc (NASDAQ:DEPO) Shows It’s 47.90% Undervalued
finance.yahoo.com - January 9 at 5:26 PM
Form 8-K DEPOMED INC For: Jan 08 - StreetInsider.comForm 8-K DEPOMED INC For: Jan 08 - StreetInsider.com
www.streetinsider.com - January 9 at 9:31 AM
Depomed Inc (DEPO) Expected to Announce Quarterly Sales of $92.77 MillionDepomed Inc (DEPO) Expected to Announce Quarterly Sales of $92.77 Million
www.americanbankingnews.com - December 27 at 1:38 PM
Depomed Inc (DEPO) Expected to Announce Earnings of $0.10 Per ShareDepomed Inc (DEPO) Expected to Announce Earnings of $0.10 Per Share
www.americanbankingnews.com - December 25 at 8:20 AM
Is Depomed Inc (NASDAQ:DEPO) A Financially Sound Company?Is Depomed Inc (NASDAQ:DEPO) A Financially Sound Company?
finance.yahoo.com - December 22 at 9:36 AM
Depomed Inc (DEPO) Receives Average Recommendation of "Hold" from AnalystsDepomed Inc (DEPO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 21 at 7:30 PM
Arthur J. Higgins Buys 75,000 Shares of Depomed, Inc. (DEPO) StockArthur J. Higgins Buys 75,000 Shares of Depomed, Inc. (DEPO) Stock
www.americanbankingnews.com - December 15 at 8:52 PM
Depomed Inc (NASDAQ:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?Depomed Inc (NASDAQ:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - December 14 at 9:36 AM
Depomed Inc (undefined:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?Depomed Inc (undefined:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - December 13 at 5:31 PM
Depomed (DEPO) Lifted to Hold at BidaskClubDepomed (DEPO) Lifted to Hold at BidaskClub
www.americanbankingnews.com - December 10 at 4:32 PM
 Analysts Anticipate Depomed, Inc. (DEPO) Will Post Quarterly Sales of $92.77 Million Analysts Anticipate Depomed, Inc. (DEPO) Will Post Quarterly Sales of $92.77 Million
www.americanbankingnews.com - December 9 at 8:26 AM
Depomed (DEPO) PT Set at $9.00 by Royal Bank Of CanadaDepomed (DEPO) PT Set at $9.00 by Royal Bank Of Canada
www.americanbankingnews.com - December 8 at 6:06 PM
Investors Purchase Large Volume of Call Options on Depomed (DEPO)Investors Purchase Large Volume of Call Options on Depomed (DEPO)
www.americanbankingnews.com - December 8 at 1:32 AM
ETFs with exposure to Depomed, Inc. : December 7, 2017ETFs with exposure to Depomed, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:47 PM
$0.10 Earnings Per Share Expected for Depomed, Inc. (DEPO) This Quarter$0.10 Earnings Per Share Expected for Depomed, Inc. (DEPO) This Quarter
www.americanbankingnews.com - December 7 at 3:39 PM
Depomed (DEPO) Receives Hold Rating from Piper Jaffray CompaniesDepomed (DEPO) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - December 7 at 7:56 AM
Depomed Executes an Exit Strategy for Its Opioid DrugDepomed Executes an Exit Strategy for Its Opioid Drug
www.fool.com - December 6 at 1:34 PM
Pre-Open Movers 12/05: (RVNC) (COLL) (DEPO) Higher; (ASNA) (DPW) (HRTX) Lower (more...)Pre-Open Movers 12/05: (RVNC) (COLL) (DEPO) Higher; (ASNA) (DPW) (HRTX) Lower (more...)
www.streetinsider.com - December 6 at 9:38 AM
Depomed (DEPO) Upgraded to "Sell" at ValuEngineDepomed (DEPO) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - December 5 at 10:50 PM
Depomed (DEPO) Upgraded to Buy at MizuhoDepomed (DEPO) Upgraded to Buy at Mizuho
www.americanbankingnews.com - December 5 at 6:34 PM
Head to Head Survey: Par Pharmaceutical Companies (PRX) and Depomed (DEPO)Head to Head Survey: Par Pharmaceutical Companies (PRX) and Depomed (DEPO)
www.americanbankingnews.com - December 5 at 12:22 PM
Benzingas Top Upgrades, Downgrades For December 5, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For December 5, 2017 - Benzinga
www.benzinga.com - December 5 at 10:10 AM
Mizuho Securities Upgrades DepoMed Inc (DEPO) to Buy - StreetInsider.comMizuho Securities Upgrades DepoMed Inc (DEPO) to Buy - StreetInsider.com
www.streetinsider.com - December 5 at 10:10 AM
Depomed, Inc. :DEPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017Depomed, Inc. :DEPO-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 10:10 AM
New Partnership for the Commercialization of Nucynta® in the U.S. TerritoryNew Partnership for the Commercialization of Nucynta® in the U.S. Territory
www.prnewswire.com - December 5 at 3:24 AM
BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium PharmaceuticalBRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
www.reuters.com - December 4 at 5:20 PM
Lawsuit for Investors Who Purchased Shares of Depomed Inc. (NASDAQ: DEPO) Announced by Shareholders FoundationLawsuit for Investors Who Purchased Shares of Depomed Inc. (NASDAQ: DEPO) Announced by Shareholders Foundation
finance.yahoo.com - November 28 at 5:20 PM
Depomed, Inc. (DEPO) Receives Consensus Recommendation of "Hold" from AnalystsDepomed, Inc. (DEPO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 26 at 8:06 PM
Depomed to Participate at the Annual Piper Jaffray Healthcare ConferenceDepomed to Participate at the Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 21 at 6:06 PM
 Brokerages Anticipate Depomed, Inc. (DEPO) Will Announce Quarterly Sales of $92.77 Million Brokerages Anticipate Depomed, Inc. (DEPO) Will Announce Quarterly Sales of $92.77 Million
www.americanbankingnews.com - November 21 at 6:24 AM
UBS AG Raises Depomed, Inc. (DEPO) Price Target to $7.00UBS AG Raises Depomed, Inc. (DEPO) Price Target to $7.00
www.americanbankingnews.com - November 12 at 9:48 AM
Depomed, Inc. (DEPO) Receives Hold Rating from Piper Jaffray CompaniesDepomed, Inc. (DEPO) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - November 11 at 9:42 AM
Depomed Inc. 2017 Q3 - Results - Earnings Call SlidesDepomed Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 10 at 5:49 PM
Depomed, Inc. – Value Analysis (NASDAQ:DEPO) : November 10, 2017Depomed, Inc. – Value Analysis (NASDAQ:DEPO) : November 10, 2017
finance.yahoo.com - November 10 at 5:49 PM
Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : November 9, 2017Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : November 9, 2017
finance.yahoo.com - November 10 at 9:30 AM
ETFs with exposure to Depomed, Inc. : November 9, 2017ETFs with exposure to Depomed, Inc. : November 9, 2017
finance.yahoo.com - November 10 at 9:30 AM
Depomed, Inc. (DEPO) Upgraded at Morgan StanleyDepomed, Inc. (DEPO) Upgraded at Morgan Stanley
www.americanbankingnews.com - November 9 at 11:54 AM
Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions - GlobeNewswire (press release)Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions - GlobeNewswire (press release)
globenewswire.com - November 9 at 12:44 AM
Depomeds (DEPO) CEO Arthur Higgins on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaDepomed's (DEPO) CEO Arthur Higgins on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 12:44 AM
Earnings Reaction History: Depomed, Inc., 87.5% Follow-Through Indicator, 10.4% Sensitive - NasdaqEarnings Reaction History: Depomed, Inc., 87.5% Follow-Through Indicator, 10.4% Sensitive - Nasdaq
www.nasdaq.com - November 9 at 12:44 AM
Edited Transcript of DEPO earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of DEPO earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 12:44 AM
Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%
finance.yahoo.com - November 9 at 12:44 AM
Depomed (DEPO) to Acquire U.S. Rights to Cosyntropin, Divest Lazanda in Pact with SlanDepomed (DEPO) to Acquire U.S. Rights to Cosyntropin, Divest Lazanda in Pact with Slan
www.streetinsider.com - November 8 at 1:42 AM
Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset TransactionsDepomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions
finance.yahoo.com - November 8 at 1:42 AM

SEC Filings

Depomed (NASDAQ:DEPO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Depomed (NASDAQ:DEPO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Depomed (NASDAQ DEPO) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.